{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:01:18Z","timestamp":1773046878942,"version":"3.50.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"R & D projects in key areas of Guangdong Province, Construction of high-level university in Guangzhou University of Chinese Medicine","award":["A1-AFD018181A29"],"award-info":[{"award-number":["A1-AFD018181A29"]}]},{"name":"Guangzhou University of Chinese Medicine National University Student Innovation and Entrepreneurship Training Project","award":["201810572038"],"award-info":[{"award-number":["201810572038"]}]},{"name":"the First Affiliated Hospital of Guangzhou University of Chinese Medicine Innovation and Student Training Team Incubation Project","award":["2018XXTD003"],"award-info":[{"award-number":["2018XXTD003"]}]},{"name":"2020 National College Student Innovation and Entrepreneurship Training Program of Guangzhou University of Chinese Medicine","award":["S202010572123"],"award-info":[{"award-number":["S202010572123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioData Mining"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) is a disease with a high incidence and a poor prognosis. Growing amounts of evidence have shown that the immune system plays a critical role in the biological processes of HCC such as progression, recurrence, and metastasis, and some have discussed using it as a weapon against a variety of cancers. However, the impact of immune-related genes (IRGs) on the prognosis of HCC remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Based on The Cancer Gene Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort) datasets, we integrated the ribonucleic acid (RNA) sequencing profiles of 424 HCC patients with IRGs to calculate immune-related differentially expressed genes (DEGs). Survival analysis was used to establish a prognostic model of survival- and immune-related DEGs. Based on genomic and clinicopathological data, we constructed a nomogram to predict the prognosis of HCC patients. Gene set enrichment analysis further clarified the signalling pathways of the high-risk and low-risk groups constructed based on the IRGs in HCC. Next, we evaluated the correlation between the risk score and the infiltration of immune cells, and finally, we validated the prognostic performance of this model in the GSE14520 dataset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 100 immune-related DEGs were significantly associated with the clinical outcomes of patients with HCC. We performed univariate and multivariate least absolute shrinkage and selection operator (Lasso) regression analyses on these genes to construct a prognostic model of seven IRGs (Fatty Acid Binding Protein 6 (<jats:italic>FABP6<\/jats:italic>), Microtubule-Associated Protein Tau (<jats:italic>MAPT<\/jats:italic>), Baculoviral IAP Repeat Containing 5 (<jats:italic>BIRC5<\/jats:italic>), Plexin-A1 (<jats:italic>PLXNA1<\/jats:italic>), Secreted Phosphoprotein 1 (<jats:italic>SPP1<\/jats:italic>), Stanniocalcin 2 (<jats:italic>STC2<\/jats:italic>) and Chondroitin Sulfate Proteoglycan 5 (<jats:italic>CSPG5<\/jats:italic>)), which showed better prognostic performance than the tumour\/node\/metastasis (TNM) staging system. Moreover, we constructed a regulatory network related to transcription factors (TFs) that further unravelled the regulatory mechanisms of these genes. According to the median value of the risk score, the entire TCGA cohort was divided into high-risk and low-risk groups, and the low-risk group had a better overall survival (OS) rate. To predict the OS rate of HCC, we established a gene- and clinical factor-related nomogram. The receiver operating characteristic (ROC) curve, concordance index (C-index) and calibration curve showed that this model had moderate accuracy. The correlation analysis between the risk score and the infiltration of six common types of immune cells showed that the model could reflect the state of the immune microenvironment in HCC tumours.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our IRG prognostic model was shown to have value in the monitoring, treatment, and prognostic assessment of HCC patients and could be used as a survival prediction tool in the near future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13040-021-00261-y","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T13:06:10Z","timestamp":1620392770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma"],"prefix":"10.1186","volume":"14","author":[{"given":"Qian","family":"Yan","sequence":"first","affiliation":[]},{"given":"Wenjiang","family":"Zheng","sequence":"additional","affiliation":[]},{"given":"Boqing","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Baoqian","family":"Ye","sequence":"additional","affiliation":[]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[]},{"given":"Xinqian","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5428-7110","authenticated-orcid":false,"given":"Xiongwen","family":"Wang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"15","key":"261_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med"},{"issue":"7","key":"261_CR2","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557\u201376. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.061.","journal-title":"Gastroenterology"},{"issue":"10127","key":"261_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2.","journal-title":"Lancet"},{"issue":"1","key":"261_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-017-0712-x","volume":"16","author":"G Khemlina","year":"2017","unstructured":"Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16(1):149. https:\/\/doi.org\/10.1186\/s12943-017-0712-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"261_CR5","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2(1):16018. https:\/\/doi.org\/10.1038\/nrdp.2016.18.","journal-title":"Nat Rev Dis Primers"},{"key":"261_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semcancer.2014.01.004","volume":"26","author":"A Shlomai","year":"2014","unstructured":"Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78\u201388. https:\/\/doi.org\/10.1016\/j.semcancer.2014.01.004.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"261_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000252780","volume":"53","author":"NH Park","year":"2010","unstructured":"Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010;53(1):20\u20138. https:\/\/doi.org\/10.1159\/000252780.","journal-title":"Intervirology"},{"issue":"1","key":"261_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","volume":"157","author":"F Kanwal","year":"2019","unstructured":"Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019;157(1):54\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.049.","journal-title":"Gastroenterology"},{"issue":"17","key":"261_CR9","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1158\/0008-5472.CAN-19-0803","volume":"79","author":"M Yarchoan","year":"2019","unstructured":"Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Karasic T, et al. Recent developments and therapeutic strategies against hepatocellular carcinoma. Cancer Res. 2019;79(17):4326\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0803.","journal-title":"Cancer Res"},{"issue":"11","key":"261_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"issue":"19","key":"261_CR11","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"issue":"1","key":"261_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"7","key":"261_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/2159-8290.CD-16-0146","volume":"6","author":"R Mandal","year":"2016","unstructured":"Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 2016;6(7):703\u201313. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0146.","journal-title":"Cancer Discov"},{"issue":"19","key":"261_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1510665.","journal-title":"N Engl J Med"},{"issue":"19","key":"261_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"7","key":"261_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","volume":"24","author":"M Inarrairaegui","year":"2018","unstructured":"Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res. 2018;24(7):1518\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0289.","journal-title":"Clin Cancer Res"},{"key":"261_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","volume":"470","author":"Y Zongyi","year":"2020","unstructured":"Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett. 2020;470:8\u201317. https:\/\/doi.org\/10.1016\/j.canlet.2019.12.002.","journal-title":"Cancer Lett"},{"issue":"2","key":"261_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","volume":"13","author":"F Heymann","year":"2016","unstructured":"Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13(2):88\u2013110. https:\/\/doi.org\/10.1038\/nrgastro.2015.200.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"261_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdw168.","journal-title":"Ann Oncol"},{"issue":"29","key":"261_CR20","doi-asserted-by":"publisher","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","volume":"114","author":"V Chew","year":"2017","unstructured":"Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114(29):E5900\u2013e5909. https:\/\/doi.org\/10.1073\/pnas.1706559114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"261_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239\u201352. https:\/\/doi.org\/10.1038\/nrc2618.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"261_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025.","journal-title":"Cell."},{"issue":"2","key":"261_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477\u2013491.e471.","journal-title":"Gastroenterology"},{"issue":"23","key":"261_CR24","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1158\/1078-0432.CCR-17-0950","volume":"23","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, et al. Characterization of the immune microenvironment in hepatocellular carcinoma. Clin Cancer Res. 2017;23(23):7333\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0950.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"261_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.29904","volume":"68","author":"Y Kurebayashi","year":"2018","unstructured":"Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025\u201341.","journal-title":"Hepatology"},{"issue":"1","key":"261_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5(1):44. https:\/\/doi.org\/10.1186\/s40425-017-0243-4.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"261_CR27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.7150\/thno.22010","volume":"8","author":"X Li","year":"2018","unstructured":"Li X, Xu W, Kang W, Wong SH, Wang M, Zhou Y, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics. 2018;8(6):1740\u201351. https:\/\/doi.org\/10.7150\/thno.22010.","journal-title":"Theranostics"},{"key":"261_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ebiom.2018.12.054","volume":"40","author":"S Shen","year":"2019","unstructured":"Shen S, Wang G, Zhang R, Zhao Y, Yu H, Wei Y, et al. Development and validation of an immune gene-set based prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318\u201326. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.054.","journal-title":"EBioMedicine"},{"issue":"23","key":"261_CR29","doi-asserted-by":"publisher","first-page":"11474","DOI":"10.18632\/aging.102548","volume":"11","author":"B Wan","year":"2019","unstructured":"Wan B, Liu B, Huang Y, Yu G, Lv C. Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging. 2019;11(23):11474\u201389. https:\/\/doi.org\/10.18632\/aging.102548.","journal-title":"Aging"},{"issue":"12","key":"261_CR30","doi-asserted-by":"publisher","first-page":"e1659094","DOI":"10.1080\/2162402X.2019.1659094","volume":"8","author":"S Yang","year":"2019","unstructured":"Yang S, Wu Y, Deng Y, Zhou L, Yang P, Zheng Y, et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. Oncoimmunology. 2019;8(12):e1659094. https:\/\/doi.org\/10.1080\/2162402X.2019.1659094.","journal-title":"Oncoimmunology"},{"key":"261_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ebiom.2019.03.022","volume":"42","author":"J Long","year":"2019","unstructured":"Long J, Wang A, Bai Y, Lin J, Yang X, Wang D, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;42:363\u201374. https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.022.","journal-title":"EBioMedicine"},{"issue":"5","key":"261_CR32","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2019.07.028","volume":"157","author":"A Moeini","year":"2019","unstructured":"Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to Chemopreventive agents. Gastroenterology. 2019;157(5):1383\u201397 e1311. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.028.","journal-title":"Gastroenterology"},{"issue":"4","key":"261_CR33","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2018.11.019","volume":"156","author":"S Liang","year":"2019","unstructured":"Liang S, Ma HY, Zhong Z, Dhar D, Liu X, Xu J, et al. NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice. Gastroenterology. 2019;156(4):1156\u201372 e1156. https:\/\/doi.org\/10.1053\/j.gastro.2018.11.019.","journal-title":"Gastroenterology"},{"issue":"7291","key":"261_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature08987","volume":"464","author":"TJ Hudson","year":"2010","unstructured":"International Cancer Genome C, Hudson TJ, Anderson W, et al. International network of cancer genome projects. Nature. 2010;464(7291):993\u20138. https:\/\/doi.org\/10.1038\/nature08987.","journal-title":"Nature"},{"issue":"Database issue","key":"261_CR35","doi-asserted-by":"publisher","first-page":"D885","DOI":"10.1093\/nar\/gkn764","volume":"37","author":"T Barrett","year":"2009","unstructured":"Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res. 2009;37(Database issue):D885\u201390. https:\/\/doi.org\/10.1093\/nar\/gkn764.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"261_CR36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.celrep.2018.11.013","volume":"25","author":"KA Zalocusky","year":"2018","unstructured":"Zalocusky KA, Kan MJ, Hu Z, Dunn P, Thomson E, Wiser J, et al. The 10,000 Immunomes project: building a resource for human immunology. Cell Rep. 2018;25(7):1995. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.013.","journal-title":"Cell Rep"},{"issue":"7","key":"261_CR37","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"261_CR38","doi-asserted-by":"publisher","first-page":"e0156594","DOI":"10.1371\/journal.pone.0156594","volume":"11","author":"C Muller","year":"2016","unstructured":"Muller C, Schillert A, Rothemeier C, et al. Removing batch effects from longitudinal gene expression - Quantile normalization plus ComBat as best approach for microarray Transcriptome data. PLoS One. 2016;11(6):e0156594. https:\/\/doi.org\/10.1371\/journal.pone.0156594.","journal-title":"PLoS One"},{"issue":"5","key":"261_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS."},{"issue":"1","key":"261_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41598-017-18850-5","volume":"8","author":"QM Imran","year":"2018","unstructured":"Imran QM, Hussain A, Lee S-U, Mun BG, Falak N, Loake GJ, et al. Transcriptome profile of NO-induced Arabidopsis transcription factor genes suggests their putative regulatory role in multiple biological processes. Sci Rep. 2018;8(1):771. https:\/\/doi.org\/10.1038\/s41598-017-18850-5.","journal-title":"Sci Rep"},{"issue":"21","key":"261_CR41","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1158\/0008-5472.CAN-17-0327","volume":"77","author":"S Mei","year":"2017","unstructured":"Mei S, Meyer CA, Zheng R, Qin Q, Wu Q, Jiang P, et al. Cistrome Cancer: a web resource for integrative gene regulation modeling in Cancer. Cancer Res. 2017;77(21):e19\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0327.","journal-title":"Cancer Res"},{"issue":"11","key":"261_CR42","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"issue":"Suppl 4","key":"261_CR43","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.","journal-title":"BMC Syst Biol"},{"key":"261_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4137\/cin.s3805","volume":"9","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Simon R. Development and validation of predictive indices for a continuous outcome using gene expression profiles. Cancer Informat. 2010;9:105\u201314. https:\/\/doi.org\/10.4137\/cin.s3805.","journal-title":"Cancer Informat"},{"issue":"9","key":"261_CR45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrc1934","volume":"6","author":"PA Farazi","year":"2006","unstructured":"Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674\u201387. https:\/\/doi.org\/10.1038\/nrc1934.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"261_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8(1):53. https:\/\/doi.org\/10.1186\/1472-6947-8-53.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"43","key":"261_CR47","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"261_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"issue":"5","key":"261_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2796.2011.02427.x","volume":"270","author":"F Ponten","year":"2011","unstructured":"Ponten F, Schwenk JM, Asplund A, Edqvist PH. The human protein atlas as a proteomic resource for biomarker discovery. J Intern Med. 2011;270(5):428\u201346. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02427.x.","journal-title":"J Intern Med"},{"issue":"1","key":"261_CR50","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"A Nagy","year":"2018","unstructured":"Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. https:\/\/doi.org\/10.1038\/s41598-018-27521-y.","journal-title":"Sci Rep"},{"issue":"1","key":"261_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","volume":"13","author":"F Chen","year":"2015","unstructured":"Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13(1):45. https:\/\/doi.org\/10.1186\/s12916-015-0278-7.","journal-title":"BMC Med"},{"key":"261_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.csbj.2014.11.005","volume":"13","author":"K Kourou","year":"2015","unstructured":"Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8\u201317. https:\/\/doi.org\/10.1016\/j.csbj.2014.11.005.","journal-title":"Comput Struct Biotechnol J"},{"issue":"11","key":"261_CR53","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","volume":"25","author":"J Chen","year":"2019","unstructured":"Chen J, Gingold JA, Su X. Immunomodulatory TGF-beta signaling in hepatocellular carcinoma. Trends Mol Med. 2019;25(11):1010\u201323. https:\/\/doi.org\/10.1016\/j.molmed.2019.06.007.","journal-title":"Trends Mol Med"},{"issue":"18","key":"261_CR54","doi-asserted-by":"publisher","first-page":"8248","DOI":"10.1073\/pnas.0912203107","volume":"107","author":"KP Lee","year":"2010","unstructured":"Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et al. The hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107(18):8248\u201353. https:\/\/doi.org\/10.1073\/pnas.0912203107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"261_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","volume":"147","author":"M Cordenonsi","year":"2011","unstructured":"Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759\u201372. https:\/\/doi.org\/10.1016\/j.cell.2011.09.048.","journal-title":"Cell."},{"issue":"5","key":"261_CR56","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/embj.201386082","volume":"33","author":"AN Lau","year":"2014","unstructured":"Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, et al. Tumor-propagating cells and yap\/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 2014;33(5):468\u201381. https:\/\/doi.org\/10.1002\/embj.201386082.","journal-title":"EMBO J"},{"key":"261_CR57","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fgene.2020.00342","volume":"11","author":"D Wang","year":"2020","unstructured":"Wang D, Liu J, Liu S, Li W. Identification of crucial genes associated with immune cell infiltration in hepatocellular carcinoma by weighted gene co-expression network analysis. Front Genet. 2020;11:342. https:\/\/doi.org\/10.3389\/fgene.2020.00342.","journal-title":"Front Genet"},{"issue":"2","key":"261_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2015.06.016","volume":"379","author":"C Su","year":"2016","unstructured":"Su C. Survivin in survival of hepatocellular carcinoma. Cancer Lett. 2016;379(2):184\u201390. https:\/\/doi.org\/10.1016\/j.canlet.2015.06.016.","journal-title":"Cancer Lett"},{"issue":"1","key":"261_CR59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1476-4598-13-209","volume":"13","author":"JG Fernandez","year":"2014","unstructured":"Fernandez JG, Rodriguez DA, Valenzuela M, et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K\/Akt enhanced beta-catenin\/Tcf-Lef dependent transcription. Mol Cancer. 2014;13(1):209. https:\/\/doi.org\/10.1186\/1476-4598-13-209.","journal-title":"Mol Cancer"},{"issue":"1461","key":"261_CR60","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1098\/rstb.2005.1696","volume":"360","author":"N Takegahara","year":"2005","unstructured":"Takegahara N, Kumanogoh A, Kikutani H. Semaphorins: a new class of immunoregulatory molecules. Philos Trans R Soc Lond Ser B Biol Sci. 2005;360(1461):1673\u201380. https:\/\/doi.org\/10.1098\/rstb.2005.1696.","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"4","key":"261_CR61","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbrc.2004.07.066","volume":"321","author":"Y Kinugasa","year":"2004","unstructured":"Kinugasa Y, Ishiguro H, Tokita Y, Oohira A, Ohmoto H, Higashiyama S. Neuroglycan C, a novel member of the neuregulin family. Biochem Biophys Res Commun. 2004;321(4):1045\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2004.07.066.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"261_CR62","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41388-019-1001-5","volume":"39","author":"N Kiavue","year":"2020","unstructured":"Kiavue N, Cabel L, Melaabi S, Bataillon G, Callens C, Lerebours F, et al. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 2020;39(3):487\u2013502. https:\/\/doi.org\/10.1038\/s41388-019-1001-5.","journal-title":"Oncogene."},{"issue":"9","key":"261_CR63","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68(9):1653\u201366. https:\/\/doi.org\/10.1136\/gutjnl-2019-318419.","journal-title":"Gut"},{"key":"261_CR64","doi-asserted-by":"publisher","first-page":"101716","DOI":"10.1016\/j.pneurobio.2019.101716","volume":"184","author":"PJ Derry","year":"2020","unstructured":"Derry PJ, Hegde ML, Jackson GR, Kayed R, Tour JM, Tsai AL, et al. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective. Prog Neurobiol. 2020;184:101716. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.101716.","journal-title":"Prog Neurobiol"},{"key":"261_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fnagi.2019.00231","volume":"11","author":"R Gargini","year":"2019","unstructured":"Gargini R, Segura-Collar B, Sanchez-Gomez P. Novel functions of the neurodegenerative-related gene tau in Cancer. Front Aging Neurosci. 2019;11:231. https:\/\/doi.org\/10.3389\/fnagi.2019.00231.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"261_CR66","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.biocel.2013.04.012","volume":"45","author":"BL Zwicker","year":"2013","unstructured":"Zwicker BL, Agellon LB. Transport and biological activities of bile acids. Int J Biochem Cell Biol. 2013;45(7):1389\u201398. https:\/\/doi.org\/10.1016\/j.biocel.2013.04.012.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"261_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0394632015572745","volume":"28","author":"SJ Chu","year":"2015","unstructured":"Chu SJ, Zhang J, Zhang R, Lu WW, Zhu JS. Evolution and functions of stanniocalcins in cancer. Int J Immunopathol Pharmacol. 2015;28(1):14\u201320. https:\/\/doi.org\/10.1177\/0394632015572745.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"261_CR68","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.msec.2017.08.075","volume":"83","author":"H Cheng","year":"2018","unstructured":"Cheng H, Wu Z, Wu C, Wang X, Liow SS, Li Z, et al. Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. Mater Sci Eng C Mater Biol Appl. 2018;83:210\u20137. https:\/\/doi.org\/10.1016\/j.msec.2017.08.075.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"1","key":"261_CR69","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s40425-019-0784-9","volume":"7","author":"G Xiao","year":"2019","unstructured":"Xiao G, Jin LL, Liu CQ, Wang YC, Meng YM, Zhou ZG, et al. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):300. https:\/\/doi.org\/10.1186\/s40425-019-0784-9.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"261_CR70","doi-asserted-by":"publisher","first-page":"E3509","DOI":"10.1073\/pnas.1802691115","volume":"115","author":"S Bugide","year":"2018","unstructured":"Bugide S, Green MR, Wajapeyee N. Inhibition of enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells. Proc Natl Acad Sci U S A. 2018;115(15):E3509\u201318. https:\/\/doi.org\/10.1073\/pnas.1802691115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"261_CR71","first-page":"1695","volume":"9","author":"S Sun","year":"2019","unstructured":"Sun S, Wang W, Luo X, Li Y, Liu B, Li X, et al. Circular RNA circ-ADD3 inhibits hepatocellular carcinoma metastasis through facilitating EZH2 degradation via CDK1-mediated ubiquitination. Am J Cancer Res. 2019;9(8):1695\u2013707.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"261_CR72","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185\u201397. https:\/\/doi.org\/10.1016\/j.ccr.2010.06.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"261_CR73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12935-018-0582-3","volume":"18","author":"J Guo","year":"2018","unstructured":"Guo J, Hao C, Wang C, Li L. Long noncoding RNA PVT1 modulates hepatocellular carcinoma cell proliferation and apoptosis by recruiting EZH2. Cancer Cell Int. 2018;18(1):98. https:\/\/doi.org\/10.1186\/s12935-018-0582-3.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"261_CR74","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.3390\/ijms21124414","volume":"21","author":"G Giannone","year":"2020","unstructured":"Giannone G, Ghisoni E, Genta S, et al. Immuno-metabolism and microenvironment in cancer: key players for immunotherapy. Int J Mol Sci. 2020;21(12):4414.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"261_CR75","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.molonc.2015.06.005","volume":"9","author":"M Bupathi","year":"2015","unstructured":"Bupathi M, Kaseb A, Meric-Bernstam F, Naing A. Hepatocellular carcinoma: where there is unmet need. Mol Oncol. 2015;9(8):1501\u20139. https:\/\/doi.org\/10.1016\/j.molonc.2015.06.005.","journal-title":"Mol Oncol"},{"issue":"4","key":"261_CR76","doi-asserted-by":"publisher","first-page":"906","DOI":"10.7150\/jca.33766","volume":"11","author":"GZ Zhu","year":"2020","unstructured":"Zhu GZ, Liao XW, Wang XK, Gong YZ, Liu XG, Yu L, et al. Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy. J Cancer. 2020;11(4):906\u201318. https:\/\/doi.org\/10.7150\/jca.33766.","journal-title":"J Cancer"},{"issue":"1","key":"261_CR77","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-018-0573-9","volume":"11","author":"B Hu","year":"2018","unstructured":"Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi GM, et al. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. J Hematol Oncol. 2018;11(1):28. https:\/\/doi.org\/10.1186\/s13045-018-0573-9.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"261_CR78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ijms18010056","volume":"18","author":"C Giovannini","year":"2016","unstructured":"Giovannini C, Bolondi L, Gramantieri L. Targeting notch3 in hepatocellular carcinoma: molecular mechanisms and therapeutic perspectives. Int J Mol Sci. 2016;18(1):56.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"261_CR79","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in Cancer. Trends Immunol. 2019;40(4):310\u201327. https:\/\/doi.org\/10.1016\/j.it.2019.02.003.","journal-title":"Trends Immunol"},{"key":"261_CR80","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3389\/fimmu.2019.01643","volume":"10","author":"Z Zong","year":"2019","unstructured":"Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1beta signaling. Front Immunol. 2019;10:1643. https:\/\/doi.org\/10.3389\/fimmu.2019.01643.","journal-title":"Front Immunol"},{"key":"261_CR81","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-015-0247-1","volume":"34","author":"L Li","year":"2015","unstructured":"Li L, Xu L, Yan J, et al. CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:129.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"261_CR82","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/hep.25907","volume":"56","author":"SL Zhou","year":"2012","unstructured":"Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56(6):2242\u201354.","journal-title":"Hepatology"},{"issue":"6","key":"261_CR83","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1053\/j.gastro.2019.01.250","volume":"156","author":"Y Wei","year":"2019","unstructured":"Wei Y, Lao XM, Xiao X, Wang XY, Wu ZJ, Zeng QH, et al. Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes Hepatoma progression in mice. Gastroenterology. 2019;156(6):1890\u2013904 e1816. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.250.","journal-title":"Gastroenterology"},{"issue":"7","key":"261_CR84","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/ijc.24556","volume":"125","author":"J Zhou","year":"2009","unstructured":"Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125(7):1640\u20138. https:\/\/doi.org\/10.1002\/ijc.24556.","journal-title":"Int J Cancer"},{"issue":"2","key":"261_CR85","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2007-01-068031","volume":"110","author":"DM Kuang","year":"2007","unstructured":"Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood. 2007;110(2):587\u201395. https:\/\/doi.org\/10.1182\/blood-2007-01-068031.","journal-title":"Blood"},{"issue":"8","key":"261_CR86","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00262-019-02355-3","volume":"68","author":"ZJ Zhou","year":"2019","unstructured":"Zhou ZJ, Xin HY, Li J, Hu ZQ, Luo CB, Zhou SL. Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection. Cancer Immunol Immunother. 2019;68(8):1223\u201333. https:\/\/doi.org\/10.1007\/s00262-019-02355-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"261_CR87","doi-asserted-by":"publisher","first-page":"e1008355","DOI":"10.1080\/2162402X.2015.1008355","volume":"4","author":"A Pedroza-Gonzalez","year":"2015","unstructured":"Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology. 2015;4(6):e1008355.","journal-title":"Oncoimmunology"},{"issue":"11","key":"261_CR88","doi-asserted-by":"publisher","first-page":"e26468","DOI":"10.4161\/onci.26468","volume":"2","author":"JC Mossanen","year":"2013","unstructured":"Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology. 2013;2(11):e26468. https:\/\/doi.org\/10.4161\/onci.26468.","journal-title":"Oncoimmunology"},{"issue":"2","key":"261_CR89","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2006.01.036","volume":"45","author":"XH Yang","year":"2006","unstructured":"Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, et al. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 2006;45(2):254\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2006.01.036.","journal-title":"J Hepatol"},{"issue":"6","key":"261_CR90","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/hep.31206","volume":"72","author":"S Itoh","year":"2020","unstructured":"Itoh S, Yoshizumi T, Yugawa K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72(6):1987.","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1186\/s13040-023-00347-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000}}],"container-title":["BioData Mining"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13040-021-00261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13040-021-00261-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13040-021-00261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:02:39Z","timestamp":1698321759000},"score":1,"resource":{"primary":{"URL":"https:\/\/biodatamining.biomedcentral.com\/articles\/10.1186\/s13040-021-00261-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1186\/s13040-021-00261-y","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13040-023-00347-9","asserted-by":"object"}]},"ISSN":["1756-0381"],"issn-type":[{"value":"1756-0381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13040-023-00347-9","URL":"https:\/\/doi.org\/10.1186\/s13040-023-00347-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential or actual conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}